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Summary
A cholesterol-lowering gene has been postulated from
familial hypercholesterolemia (FH) families having het-
erozygous persons with normal LDL levels and homo-
zygous individuals with LDL levels similar to those in
persons with heterozygous FH. We studied such a family
with FH that also had members without FH and with
lower-than-normal LDL levels. We performed linkage
analyses and identified a locus at 13q, defined by mark-
ers D13S156 and D13S158. FASTLINK and GENE-
HUNTER yielded LOD scores 15 and 14, respectively,
whereas an affected-sib-pair analysis gave a peak mul-
tipoint LOD score of 4.8, corresponding to a P value
of . A multipoint quantitative-trait-locus561.26# 10
(QTL) linkage analysis with maximum-likelihood bi-
nomial QTL verified this locus as a QTL for LDL levels.
To test the relevance of this QTL in an independent
normal population, we studied MZ and DZ twin sub-
jects. An MZ-DZ comparison confirmed genetic vari-
ance with regard to lipid concentrations. We then per-
formed an identity-by-descent linkage analysis on the
DZ twins, with markers at the 13q locus. We found
strong evidence for linkage at this locus with LDL
( ), HDL ( ), total cholesterol (P ! .0002 P ! .004 P !
), and body-mass index ( ). These data.0002 P ! .0001
provide support for the existence of a new gene influ-
encing lipid concentrations in humans.
Received July 7, 1999; accepted October 1, 1999; electronically
published January 4, 2000.
Address for reprints and correspondence: Dr. Friedrich C. Luft,
Franz Volhard Clinic, Wiltberg Strasse 50, 13125 Berlin, Germany.
E-mail: luft@fvk-berlin.de
* The first two authors contributed equally to this work.
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6601-0019$02.00
Introduction
Elevated serum LDL concentrations are a major cause
of coronary atherosclerosis (Grundy 1997). Support for
LDL’s fundamental role derives from the discovery of
the LDL receptor. Familial hypercholesterolemia (FH) is
the most common (frequency 1/500) autosomal-domi-
nant disease affecting lipid metabolism (Brown and
Goldstein 1986); heterozygous affected persons have
LDL levels twice normal levels and develop premature
coronary disease, whereas homozygous individuals have
sixfold-elevated LDL levels and often die of cardiovas-
cular disease at age !20 years. Cholesterol-synthesis in-
hibitors have exerted a gratifying effect on the course of
atherosclerosis (Gould et al. 1998). However, even more
ingenious would be endogenous mechanisms that have
a similar cholesterol-lowering effect. Hobbs et al. (1989)
presented strong evidence supporting the notion that a
“lipid-lowering” gene exists. They described a family
with FH that featured affected members with lower-
than-expected LDL concentrations. We recently identi-
fied a large Arab family with FH whose FH-affected
family members often have normal LDL concentrations
and do not manifest atherosclerosis. Thus far, 96 family
members have been phenotyped and genotyped. The
LDL-receptor mutation in this family has been identified
elsewhere (Davis et al. 1986). The defect resides in the
receptor’s cytoplasmic tail and causes defective receptor
internalization with almost-absent LDL-receptor activ-
ity. In the present investigation, we tested the hypothesis
that a “cholesterol-lowering” gene exists in this family,
by means of linkage analysis. We then studied a second,
normal population and verified the relevance of our find-
ings. We present evidence that such a gene indeed exists
on chromosome 13q.
Methods
The FH family is Moslem and Arab and resides in
Israel. Ninety-six members were examined after written
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informed consent was obtained. Venous blood was used
for DNA extraction and automated serum lipid mea-
surements. LDL-cholesterol levels were calculated by use
of the Friedewald formula (Friedewald et al. 1972). Re-
peated blood sampling and determinations of lipopro-
tein concentrations were done to ensure validity of the
measurements prior to initiation of cholesterol-lowering
therapy. At the time of the determinations, the subjects
ingested a diet typical for the region, which is relatively
high in fat and dairy products. We have subsequently
advised persons with LDL-receptor mutations to adopt
a low-fat diet and have begun pharmacological treat-
ment as clinically indicated.
After we had determined the FH status (either het-
erozygous, homozygous, or not affected with FH) in all
the family members, we examined the relationship be-
tween LDL cholesterol, age, gender, and body-mass in-
dex (BMI). We found no effects of gender and BMI in
FH-heterozygous individuals; however, there was amod-
est age-related effect on LDL values in FH heterozygotes
(see below). We also observed that the variation in LDL
values increased with age. We then corrected the LDL-
cholesterol values for age. The age-related effect on the
variation was greater than the age-related effect on LDL
values per se. We calculated the residuals of the LDL-
cholesterol values by using standard linear regression,
with age as an independent variable. This was done sep-
arately for FH-heterozygous affected and normal indi-
viduals in this family. We next corrected these residuals
for age. This procedure allowed us to adjust the LDL
values both for age and age-related variability. With
these values we performed commingling analysis in the
pedigree by using ILINK (Lathrop et al. 1984). These
results allowed us to define FH-heterozygous persons
with corrected LDL values150 mg/dl as “affected” by
a putative cholesterol-lowering gene (for justification,
see the Results section). Those persons having LDL val-
ues 1150 mg/dl were defined as not affected by this gene.
We did not have sufficient FH-homozygous subjects to
correct their LDL values for age. Those homozygous
persons with an LDL-cholesterol concentration 500
mg/dl were classified as “affected” with the cholesterol-
lowering gene, whereas those with LDL levels 1500 mg/
dl were classified as not affected. We picked these values
of LDL concentrations because FH-heterozygous pa-
tients rarely have LDL concentrations 1500 mg/dl and
because !500 mg/dl in homozygous FH individuals are
decidedly unusual. Moreover, such homozygous FH pa-
tients were asymptomatic in an earlier study (Sprecher
et al. 1984). In persons carrying no FH mutation, there
was a clear correlation between LDL values and age.
LDL values were also higher in men than in women.
Therefore, in this group the definition of “affected by
the cholesterol-lowering gene” was more complex. We
used the standardized linear-regression residuals of LDL
versus age, done separately for men and women, to de-
fine persons as affected if LDL values were sharply (1.5
SD) below the values predicted on the basis of their age
and gender.
PCR-based mutation screening was performed in all
96 family members to categorize them as homozygous,
heterozygous, or unaffected for FH. Genotyping was
done with the ABI PRISMGenotyping System, including
the Linkage Mapping Set, version 2 (LMS V2), PCR
9600 thermocyclers, the 877 Integrated Thermocycler,
ABI DNA Sequencers, and GENESCAN and GENO-
TYPER software from PE Biosystems. The PCR primers
contained in the LMS V2 amplify dinucleotide-repeat
loci spaced at ∼10 cM. The markers are organized in a
set of 28 panels, with 10–19 primer pairs per panel,
whose products can be electrophoresed and detected in
a single lane. The LMS V2 set includes forward primers
that are labeled with 6-FAM, HEX, and NED (replacing
TET) fluorescent dyes. These dyes can be distinguished
by their different spectral properties. The LMS V2 re-
verse primers were redesigned to overcome the problem
of nontemplated nucleotide adenylation, also known as
“plus-A.” All markers were amplified under a common
set of PCR conditions, by use of the True Allele PCR
mix (PE Biosystems) containing AmpliTaq Gold DNA
Polymerase and a final MgCl2 concentration of 2.5 mM,
with a 55C annealing temperature. Electrophoresis and
detection were done on an ABI 377 DNA Sequencer
equipped with GENESCAN 2.1 software. Genotyping
was performed with GENOTYPER 2.1 software. Gen-
otypes were exported as a text file for subsequent linkage
analysis.
We sought to determine whether any genes whose
products are known to affect the interaction of LDLwith
its receptor cosegregate with the cholesterol-lowering
phenotype. We looked for linkage between the choles-
terol-lowering phenotype and the gene for the LDL re-
ceptor itself, as well as the genes for the receptor’s two
ligands, apo B-100 and apo E. Apo B gene mutations
are known to cause low plasma-cholesterol levels (Col-
lins et al. 1988). Apo B VNTR genotyping and apo E
genotyping were done as described elsewhere (Hixon
and Vernier 1990).
We selected 18 individuals for the first genotyping
scan, to form a core pedigree. The selected group should
contain a goodly number of closely related affected per-
sons, which should minimize the danger of misspecifying
the pedigree structure and should yield amaximumLOD
score 13. The actual choice was made by visual inspec-
tion and by verification of the latter criterion by simu-
lation analysis.
For total-genome scanning, we used FASTLINK (Cot-
tingham et al. 1993), version 4.0, for the two-point anal-
ysis in the core pedigree. GENEHUNTER (Kruglyak et
al. 1996) was used for multipoint analysis in split ver-
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Figure 1 Frequency distribution of the subjects, in terms of their
corrected LDL-cholesterol concentrations. Commingling analysis by
use of ILINK allowed us to establish phenotypic criteria in terms of
being “affected” by a putative cholesterol-lowering gene (LDL cho-
lesterol !150 mg/dl).
Table 1
Demographic Information on Individuals in the Core Pedigree
INDIVIDUAL AGEa (SEX)
LDL (AGE
AND FH
ADJUSTED)b
(mg/dl) FH
Apo
GENOTYPE
ApoB ApoEc
IV:1 62 years (F) 341 (238) 1 1,2 3,3
IV:2 63 years (M) 111* (126*) 1 1,3 3,3
IV:4 57 years (F) 71* (104*) 1 3,3 3,3
IV:5 54 years (M) 135* (137*) 1 1,3 3,4
IV:6 55 years (M) 190 (167) 1 1,3 3,4
IV:7 55 years (F) 223 (185) 1 1,4 3,3
IV:8 60 years (F) 221 (181) 1 1,2 3,3
IV:9 65 years (M) 159 (ND) 0 3,3 3,3
V:1 42 years (F) 140* (140*) 1 2,3 3,3
V:3 35 years (F) 165 (159) 1 2,3 ND
V:5 ) (F) 207 ()) 1 1,1 3,4
V:6 24 years (F) 136* (136*) 1 1,1 3,3
V:7 32 years (M) 211 (197) 1 1,1 3,4
V:8 32 years (F) 187 (178) 1 2,3 3,3
VI:1 3 years (F) 142* (143*) 1 2,2 3,3
VI:2 7 years (M) 111* (85*) 1 1,3 3,3
VI:3 5 years (M) 126* (110*) 1 1,3 3,3
VI:4 3 years (M) 115* (80*) 1 1,2 3,4
a An ellipsis ()) denotes that the individual’s data were unknown.
b Values for individuals with the putative cholesterol-lowering gene
are denoted by an asterisk (*). ND = not done.
c ND = not done.
sions of both the core and extended pedigrees. GENE-
HUNTER is not able to accommodate the multiple loops
in the extended pedigree unless the pedigree is split into
subunits. We therefore also elected to perform an af-
fected-sib-pair analysis by using a maximum-likelihood
binomial (MLB) statistic as implemented in a modified
version of GENEHUNTER (Abel and Mu¨ller-Myhsok
1998). The MLB statistic is a maximum-likelihood ra-
tio–based sibship method especially geared to the anal-
ysis of sibships with multiple affected persons. The anal-
ysis is based on the estimation of a single parameter, a,
which is related to p, the proportion of alleles shared
by the sib pair, according to the relationship p = 1
. The model used for parametric analysis was2a (1 a)
an autosomal-recessive–type model with an allele fre-
quency of .01. We scrutinized all regions with a thresh-
old p value of .1. Within the regions of interest, all 86
informative family members were genotyped. Because of
computational restrictions, parametric multipoint link-
age analysis within this highly consanguineous family
was possible only by use of two flanking markers. When
the results of the MLB analysis are considered, it should
be noted that the LOD score obtained when this analysis
is performed may be readily transformed into a x2 var-
iable, by multiplying it by . This x2 variable2 # ln (10)
asymptotically follows a 50:50 distribution of 0 and 1
df.
We also subjected our total genome–scan data to a
test for linkage in terms of a quantitative-trait locus
(QTL), using the novel QTL approach as implemented
in MLBQTL (Alcais and Abel 1999). We chose this anal-
ysis because, contrary to the classically used Haseman-
Elston approach, the MLBQTL does not necessarily
assume a normal distribution of the trait or derivedmea-
sures. For the analysis, we considered the phenotypic
information from FH-pedigree members, who, after cor-
rection for gender, status at the FH locus, age, and the
known covariate BMI, were 1 SD above or below the
mean. Thus, we applied a combined discordant and con-
cordant sib-pair QTL analysis.
Finally, to test the hypothesis that the cholesterol-
modifying gene is present in the general population, we
performed studies in 122 pairs of MZ and 100 pairs of
DZ twins and in available parents of the DZ twins. The
subjects were all healthy, normotensive white individuals
recruited from various parts of Germany. The protocol
was approved by Humboldt University’s committee on
the protection of human subjects, and written informed
consent was obtained from all participants. Persons with
histories of familial lipid disorders were excluded. De-
tails of our twin analysis have been published elsewhere
(Knoblauch et al. 1997). Blood was obtained for total
cholesterol, HDL, and triglycerides, and LDL was cal-
culated by use of the Friedewald equation (Friede-
wald et al. 1972). Blood was also obtained for the
determination of zygosity and other molecular-genetic
studies. Microsatellite markers D13S1306, D13S170,
D13S1241, D13S265, D13S159, and D13S158, span-
ning the “cholesterol-lowering gene” locus on chro-
mosome 13, were analyzed.
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Figure 2 Extended pedigree showing all 96 individuals from whom lipid measurements were obtained. The subject’s pedigree identification
number is given, as well as the actual LDL-cholesterol concentration (mg/dl). FH-heterozygous individuals are half-blackened, whereas ho-
mozygous persons are fully blackened. Gray symbols represent those individuals selected for the core pedigree. Individuals with FH bearing
the cholesterol-lowering gene are denoted by an asterisk (*). Their LDL-cholesterol levels are decidedly lower than would be expected for
patients with FH.
For the twin linkage analysis, DZ pairs and their par-
ents were included as described elsewhere (Busjahn et
al. 1999). Analysis was done by use of a variance-com-
ponent approach (Eaves et al. 1996). Phenotypic vari-
ance was decomposed into variance due to genetic back-
ground (A), variance due to the QTL effect (Q), and
environmental variance (E): . For2 2 2Var = A Q  E
the three possible identical by descent (IBD) states
(sharing zero, one, or two alleles), covariance of a sib
pair was then defined by 2Cov = 0.5A , Cov =IBD0 IBD1
and . To improve2 2 2 20.5A  0.5Q , Cov = 0.5A QIBD2
estimates of total variance and genetic background, MZ
twins were included in the analysis, with the covariance
defined as .2 2Cov = A QMZ
To test for a QTL effect, the difference in model fit
for models with and without a QTL effect was calculated
as a x2 statistic. For each sib pair and each locus, the
proportion of alleles IBD, based on parental genotypes
and independent allele-frequency estimates, was calcu-
lated by use of a multipoint approach, as implemented
in MAPMAKER/SIBS (Kruglyak and Lander 1995). The
higher power of the variance-covariance–based analysis,
compared with the squared trait differences–based ap-
proach by the Haseman-Elston method, has been shown
in a recent simulation study (Fulker and Cherny 1996).
Because we used a candidate-gene approach, we ac-
cepted to test for significant linkage, in accor-P ! .01
dance with the criteria defined by Lander and Kruglyak
(1995).
Heritability was estimated by structural equation
modeling (Neale and Cardon 1992, p. 496), by use of
the MX program developed by Neale (1997). The var-
iability of any given phenotype within a population can
be decomposed into genetic influences (A), environmen-
tal influences shared by the twins within a family (C),
and effects of random environment (E): 2Var = A 
. For MZ and DZ, the covariance of their phe-2 2C  E
notype is given by and2 2Cov = A  C Cov =MZ DZ
. Genetic, as well as environmental, effects2 20.5A  C
were estimated by the best-fitting model as selected by
the x2 value. Statistical analysis was conducted by use
of the SPSS program. Adjustment of phenotypic values
for sex and age was done by multiple linear regression,
with the unstandardized residuals as the corrected phe-
notypes. In case of significant deviations from a normal
distribution, the appropriate transformations were ap-
plied prior to analysis.
Results
In the FH-heterozygous family members, we found a
modest, albeit significant ( ), effect of age on LDLP ! .04
values, allowing us to correct for the effects of age. Fig-
ure 1 shows the frequency distribution of corrected LDL-
cholesterol values in FH-heterozygous subjects. Com-
mingling analysis using ILINK gave significant evidence
( ) against a unimodal distribution of the cor-P ! .03
rected LDL values. The mean LDL value of the lowest
genotypic distribution in the model was 138 mg/dl; the
SD was 29 mg/dl. The other means were close together,
at 198 and 203 mg/dl, respectively. This finding was
interpreted as indicating a recessive trait, which was in
accordance with a segregation analysis that used LOKI
(Heath 1997). The classification threshold (150 mg/dl)
was calculated as the 5th percentile in the group of per-
sons heterozygous for the putative cholesterol-lowering
gene. This approach gave a 95% certainty of correct
classification for heterozygous individuals. We classified
FH-heterozygous persons with values 150 mg/dl as
affected by a cholesterol-lowering trait. The extended
pedigree is shown in figure 2. FH-heterozygous individ-
uals are indicated, as well as the uncorrected LDL-cho-
lesterol values. Persons affected by the cholesterol-low-
ering gene are also indicated.
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Table 2
Two-Point LOD Scores in the Core Pedigree
MARKER
LOD SCORE AT v =
0 .01 .05 .1 .2 .3 .4
D13S175  .48 .32 .56 .55 .36 .17
D13S217  5.82 2.75 1.46 .42 .07 .02
D13S171  4.15 1.72 .74 .05 .1 .09
D13S263  7.04 2.95 1.38 .19 .15 .16
D13S153  7.06 2.92 1.35 .18 .14 .15
D13S156  2.2 .37 .35 .74 .58 .27
D13S1306 .55 .67 .85 .84 .62 .34 .12
D13S789  2.84 1.18 .4 .16 .25 .16
D13S170  1.94 2.29 2.14 1.53 .83 .26
D13S271  .13 1.17 1.38 1.19 .77 .33
D13S265  .67 1.56 1.71 1.44 .92 .39
D13S794  1 .68 1.09 1.03 .62 .21
D13S795  1.93 .54 0 .28 .22 .1
D13S1300 .54 .58 .88 1 .81 .46 .16
D13S129 3.67 3.69 3.56 3.2 2.25 1.21 .39
D13S125 .29 .09 .4 .58 .52 .29 .09
D13S254  3.06 3.32 3.06 2.23 1.29 .49
D13S154  1.2 .49 1 1 .56 .14
D13S1241  1.67 2.25 2.22 1.67 .92 .29
D13S786  2.54 .41 .33 .67 .54 .26
D13S159  1.82 .19 .81 .95 .67 .3
D13S158  2.16 .22 .43 .63 .39 .12
D13S173  1.97 .65 .18 .08 .09 .05
D13S285  5.04 2.39 1.22 .31 .03 .02
Table 3
Two-Point LOD Scores in the Whole Pedigree (Affecteds Only)
MARKER
LOD SCORE AT v =
0 .01 .05 .1 .2 .3 .4
D13S175 .41 .35 .17 .06 .02 .03 .01
D13S217 1.68 1.54 1.12 .78 .39 .18 .07
D13S171 1.64 1.51 1.11 .79 .41 .2 .07
D13S263 1.63 1.42 .89 .51 .15 .01 .03
D13S153 2.84 2.52 1.67 1.03 .37 .08 .01
D13S156 .12 .03 .32 .42 .36 .2 .07
D13S1306 .9 .89 .82 .71 .46 .23 .07
D13S789 .69 .67 .6 .5 .33 .18 .07
D13S170 1.63 1.63 1.51 1.29 .78 .36 .09
D13S271 1.59 1.54 1.34 1.11 .68 .34 .11
D13S265 2.37 2.3 2 1.65 1.04 .55 .19
D13S794 1.34 1.3 1.15 .96 .58 .27 .07
D13S795 .58 .57 .53 .47 .31 .15 .04
D13S1300 1.78 1.72 1.45 1.14 .62 .26 .06
D13S129 1.96 1.9 1.67 1.36 .8 .38 .11
D13S125 .68 .66 .59 .51 .35 .2 .08
D13S254 1.48 1.49 1.42 1.25 .83 .44 .15
D13S154 .72 .71 .65 .54 .31 .12 .01
D13S1241 .02 .14 .38 .45 .33 .15 .02
D13S786 .71 .77 .86 .82 .6 .33 .12
D13S159 .44 .56 .78 .81 .64 .37 .14
D13S158 1.15 1 .63 .39 .18 .09 .05
D13S173 .46 .44 .38 .31 .19 .09 .02
D13S285 .5 .43 .25 .11 .01 .01 .02
We first looked for linkage between the cholesterol-
lowering–gene locus and the gene for the LDL receptor
itself, as well as the genes for the receptor’s two ligands,
apo B-100 and apo E. No significant evidence for linkage
was found with either of these candidates. We next con-
structed a core pedigree consisting of 29 individuals
composed of normal and FH-heterozygous individuals
only. A subset of 18 individuals from this core pedigree
(table 1) was genotyped for 300 microsatellite markers.
Markers on eight chromosomal regions (two regions
each on chromosomes 1 and 12 and one region each on
chromosomes 6, 13, 16, and 18) were candidates (P !
) for linkage to the low-cholesterol phenotype..1
Eighty-six individuals from the 96-member pedigree
were then used to test for linkage with additional mark-
ers from the eight chromosomal regions. Ten persons
were not included because they were not informative for
the linkage analysis. In the core pedigree, a maximum
pairwise LOD score of 3.69 was obtained with marker
D13S129, at a recombination fraction (v) of .01. Also
in the core pedigree, marker D13S254 yielded a maxi-
mum pairwise LOD score of 3.32 at (table 2).v = .05
The maximum two-point LOD score in the entire ped-
igree was 5.22 with marker D13S129 at . Twov = .05
additional markers exceeding the critical threshold of
3.0 were D13S265, with a LOD score of 4.06 at v =
, and D13S1241, with a LOD of 3.01 at . We.10 v = .10
also analyzed the data set as an “affecteds-only” analysis
(table 3). Multipoint linkage analysis in the extended
pedigree was hampered by the complex consanguinity
and by possible additional, unrecognized interconnec-
tions. Nevertheless, a three-point analysis using FAST-
LINK gave a LOD score of 5.67 at a location close to
D13S129. GENEHUNTER yielded a maximum multi-
point LOD score of 4.50 at , at the neighboringv = .0
marker D13S1300, which flanks D13S129. To circum-
vent potential limitations of FASTLINK and GENE-
HUNTER, we performed the affected-sib-pair analysis
with the MLB statistic. Significant positive LOD scores
were obtained exclusively for markers from the same
region on chromosome 13, as shown in figure 3. The
maximum multipoint LOD score (when the MLB sta-
tistic was used) was 4.82 (corresponding to a nominal
P value of ) at D13S1241. This region dem-61.26 # 10
onstrated complete sharing among affected sibs. The
critical region on the basis of the “zmax-2” method for
this analysis, was defined by two polymorphic markers,
D13S156 and D13S158, which are ∼37 cM apart. We
next verified our findings by showing independently that
the 13q locus is a QTL for LDL concentrations in this
pedigree. QTL analysis using MLBQTL gave a maxi-
mum LOD of 4.23, with the peak located at D13S794
and with the “zmax-2” support interval also extending
from D13S156 to D13S158. No other significant peaks
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Figure 3 Results of linkage analysis using MLB and MLBQTL in the FH pedigree, together with linkage results for LDL in the DZ twins
(P values have been transformed into LOD scores). In the twins, the peak level of significance was .0002, right on marker D13S1241.
(LOD score 13) in the genome were identified by use of
the QTL analysis. One region on chromosome 6 (around
D6S257) showed a LOD score of 1.95. Haplotype data
show the cosegregation of the 13q markers with the
phenotype, as shown in figure 4. The gray-shaded zone
represents the area of complete allele sharing within all
affected sib pairs. Nevertheless, there was no common
region of homozygosity in all affected pedigreemembers.
Two persons unaffected by the cholesterol-lowering trait
have the same haplotypes as their affected siblings. These
two individuals may represent incomplete penetrance.
To test the relevance of our findings, we performed a
twin analysis in German subjects (table 4). Females were
twice as common as males. The subjects were young
adults of normal height, weight, and BMI. Total cho-
lesterol, HDL, LDL, and triglyceride values were all
within normal limits. Table 4 also shows the results of
the heritability analysis. A major genetic effect was dem-
onstrated for all lipid parameters, although strong en-
vironmental effects were also shown. Table 5 shows the
results of the linkage analysis. Significant linkage was
shown for HDL, LDL, total-cholesterol concentrations,
and BMI. Figure 3 gives the results of the variance-
component multipoint linkage analysis for LDL. The
peak level of significance was .0002, right on marker
D13S1241. For this locus, the lower boundary-effect es-
timates, on a 95% confidence interval, for LDL choles-
terol and BMI were ∼26% and ∼22%, respectively.
Discussion
The important finding in our study is that we were
able to identify significant linkage between a locus on
chromosome 13q and a putative cholesterol-lowering
gene in a family with FH that had members with un-
expectedly low LDL concentrations. To solidify our re-
sults, we used more than one linkage analysis, including
parametric linkage analysis, multipoint linkage analysis,
an affected-sib-pair method, and a QTL analysis. At first
glance, there appears to be a discrepancy between the
parametric analysis and the affected-sib-pair analysis.
The peak LOD score from MLB and QTLMLB analysis
is located near D13S786. This marker and flanking
markers yielded a LOD score of  in the two-point
linkage analysis. This result may be due to uncertainties
in the genetic models used in the analysis. More specif-
ically, these problems may reside in the penetrance ma-
trix. None of these recombination events was present in
an affected individual. This fact is shown by the table
of LOD scores from the affecteds-only analysis in the
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Table 4
Clinical Data and Serum Lipid Values for the German Twin Sample
Variable MZ Twins DZ Twins
Genetic
Effect P
n (pairs) 122 100
Age (years) 34  15 34  13
Sex (male/female) 80/164 60/140
Height (cm) 169  9 170  9
Weight (kg) 67  13 71  14
BMI (kg/m2) 23  4 24  4 .97 .01
Total cholesterol (mg/dl) 183  39 193  42 .64 .01
HDL cholesterol (mg/dl) 51  14 57  17 .59 .01
LDL cholesterol (mg/dl) 115  34 115  32 .66 .01
Triglycerides (mg/dl) 87  67 100  64 .72 .01
NOTE.—Data are unless otherwise indicated.mean SD
Table 5
Results of Linkage Analysis
Model x2 Model Difference (P)a
Total cholesterol 13.63 (.0002)
HDL cholesterol 8.20 (.004)
LDL cholesterol 13.60 (.0002)
Triglycerides 6.39 (.011)
BMI 14.26 (.0001)
a The difference is between models with
and without a QTL effect; P values are for
the corresponding QTL effect.
entire pedigree (table 3). We observed a series of 10
markers (D13S1306–D13S254) showing positive LOD
scores, with in every case.v = 0
We interpreted the lack of a common homozygosity
region in this family as being due to a high frequency
of this modifier gene in the general population. A rough
estimate suggests a population allele frequency of .10,
which is also the value used for the linkage analysis.
Furthermore, the family that we studied is from an iso-
lated but stable population. The expected region of ho-
mozygosity may be detectable only at the intragenic
level, as has been described by others (Aksentijevich et
al. 1999). Aksentijevich et al. (1999) performed hap-
lotype studies of familial Mediterranean fever in the Ash-
kenazi Jewish population. There were two completely
different haplotypes (for six markers) in that study, both
carrying the sequence alteration V726A in the same fam-
ily. Similarly, Aksentijevich et al. (1999) point out that
the mutation E148Q may extend back to a common
relatively ancient founder. Several distinct haplotypes
carrying this mutation have been observed. However, at
the intragenic level, the single nucleotide–polymorphism
motifs converged. Those investigators concluded that an
ancestor common to all the E148Q carriers may have
lived some 1,500–2,000 years ago, a time span not un-
realistic for this part of the world. For these reasons, we
believe that our failure to identify a homozygosity region
does not detract from the significance of our findings.
Another possible explanation for our findings is related
to the frequency of the mutation. A commonly occurring
mutation could very well enter through different path-
ways even in a sibship, especially through affected par-
ents (Veske et al. 1996). There are several examples of
such sibships in our study.
To test whether this new locus is of any relevance to
the general population, we performed a second, inde-
pendent study in MZ and DZ twins. We verified earlier
findings that LDL, HDL, total cholesterol, triglycerides,
and BMI are all strongly influenced by genetic variance
(Knoblauch et al. 1997). An IBD linkage analysis in DZ
twins yielded strong evidence in support of the 13q locus
as being a QTL for lipid concentrations, as well as for
BMI. Moreover, the effect of this locus on LDL choles-
terol was estimated to be ∼26%. We believe that these
studies are unique, since we not only mapped a here-
tofore unknown gene but also proved, in principle, its
effects and relevance in a completely unrelated, normal
population.
Our results extend earlier studies indicating the ex-
istence of a cholesterol-lowering gene. Hobbs et al.
(1989) described a similar unusual kindred with FH, in
which one-third of affected relatives had normal LDL
levels. Those investigators concluded that the low-cho-
lesterol phenotype was most consistent with a single
dominant gene suppressing the hypercholesterolemic ef-
fect of the LDL-receptor mutation in the family that they
studied. They also excluded the LDL-receptor gene and
the apo B-100 and apo E genes, by linkage analysis.
Nora et al. (1985) also described a family with FH with
normal cholesterol values in obligate-heterozygous pa-
tients with FH. Conceivably, by expansion of these ped-
igrees, a linkage analysis to verify and extend our results
could be performed.
To test for linkage, we first performed an affecteds-
only analysis on the core pedigree, which yielded a prom-
ising LOD score of 2.31 at D13S170.We next performed
a parametric two-point linkage analysis in the core ped-
igree, assuming complete penetrance and including un-
affected individuals according to our phenotypic defi-
nitions, which yielded two closely neighboring markers
with LOD scores 13 at markers D13S254 and D13S129.
We then examined the extended pedigree according to
a conventional, parametric, two-point-linkage tech-
nique, which yielded a LOD score of 5.22 at marker
D13S129. Three-point analysis using FASTLINK gave a
LOD score of 5.67 at a location close to D13S129. A
GENEHUNTER analysis gave a LOD score of 4.50 in
the area of this same marker. An affected-sib-pair ap-
proach using the MLB statistic provided a LOD score
of 4.82, corresponding to a nominal P value of
. We believe that our approach, using sev-61.25# 10
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eral methods, provides robust evidence that the choles-
terol-lowering gene resides on chromosome 13q.
Since LDL values are a continuous trait, our definition
of being affected or unaffected by the cholesterol-low-
ering gene is potentially arbitrary until we identify the
responsible gene mutation. We took care to consider the
effects of age, gender, and BMI on LDL values. Our
affected cutoff point is in accord with the accepted def-
inition of FH among close relatives, for persons age 118
years, which is 165 mg/dl (Williams et al. 1996). Ad-
ditional support in favor of our phenotypic definition
comes from the analysis of corrected LDL concentrations
of Druze and Christian-Lebanese FH-heterozygous in-
dividuals, who consume a diet very similar to that of
the Moslem-Arab individuals whom we studied. The
FH-heterozygous persons defined as affected for the cho-
lesterol-lowering gene in our study had corrected LDL
concentrations within the range seen in persons without
FH who were from the Druze and Christian-Lebanese
families with FH that have been described elsewhere
(Leitersdorf et al. 1991). In contrast to the situation for
individuals with FH in China (Sun et al. 1994) and Tu-
nisia (Slimane et al. 1993), who, because of the ingestion
of a low-fat diet, can have similarly low LDL values, we
can rule out any dietary effect. The diet of the family
with FH examined by us does not differ from the usually
high-fat diet ingested by other people from this area.
Their diet is no different from that ingested by the Chris-
tian-Arab population residing in Lebanon and described
initially by Khachadurian (1964). Interestingly, Khach-
adurian observed that, with the exception of four FH-
homozygous patients from a single family, 50 other FH-
homozygous patients all had cholesterol values 1600mg/
dl. The families that he studied had a null mutation
similar to the mutation in the family that we studied,
which results in an almost completely nonfunctioning
LDL receptor. Finally, in the family that we studied, lipid
values from persons not affected by the putative cho-
lesterol-lowering gene are in the expected range, as in
other families with FH in Israel.
The potential arbitrariness of our phenotype—and the
clue that the allele in question might be common—led
us first to demonstrate that the 13q locus is indeed a
QTL in the pedigree in question and then to prove that
the 13q locus has relevance to lipid concentrations in
the general population. Relevance for the general pop-
ulation can usually not be shown for monogenic dis-
eases. FH, for example, is caused by literally hundreds
of separate mutations in the LDL-receptor gene (Hobbs
et al. 1992). However, linkage of the LDL receptor–gene
locus to LDL serum concentrations in normal subjects
or in patients without FH and with coronary disease has
not been convincingly shown (Knoblauch et al. 1997).
DZ twins are a particularly powerful sib-pair model,
because of identical ages and a shared environment, at
least during childhood. Sample size can be sharply re-
duced, without a loss of power, when DZ-twin siblings
are examined. The utility of DZ twins in the quantitative
sib-pair linkage–analysis approach to genes relevant to
cardiovascular disease was recently demonstrated by
Austin et al. (1998), who found linkage between the
microsomal triglyceride-transfer–protein gene locus and
plasma triglyceride concentrations. In addition, our ear-
lier twin study (Knoblauch et al. 1997) showed evidence
for linkage between the macrophage-scavenger–receptor
gene locus and HDL concentrations. Our linkage results
are almost two orders of magnitude below the criteria
suggested by Lander and Kruglyak (1995), who, for a
successful replication of an earlier result, called for a P
value of .01.
We have yet to identify potentially interesting candi-
date genes in this chromosomal area. As part of an effort
to dissect the genetic factors involved in cholesterol ho-
meostasis, a genomewide analysis with a mouse model
revealed several new candidate genes (Welch et al. 1996).
However, none of these loci are syntenic to the homolo-
gous human chromosome (13q). We believe that low
cholesterol levels in the affected individuals in this ped-
igree may be caused by a single gene. Although this
hypothesis is speculative, we suggest that this gene may
act on lipoprotein assembly in the liver. Functional stud-
ies will be required in order to test this issue. Elucidation
of this gene may give new insight into mechanisms of
lipoprotein regulation and protection from atheroscle-
rosis and could lead to a new class of cholesterol-low-
ering agents.
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